Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
ETF Daily News10d
Alkermes (NASDAQ:ALKS) Rating Reiterated by Piper Sandler
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
Alkermes: Strong Buy Rating Amidst Short-term Challenges and Long-term Growth Potential
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
PR Newswire13d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...
Alkermes (NASDAQ:ALKS) Given New $43.00 Price Target at Cantor Fitzgerald
Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...
Business Insider9d
Alkermes (ALKS) Gets a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Alkermes (ALKS – Research Report) on October 25 and set a price target of $25.00. The company’s shares closed last Friday at $26.09.
Nasdaq12d
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had ...
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...
Zacks.com on MSN13d
Alkermes (ALKS) Lags Q3 Earnings and Revenue Estimates
Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures ...